Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Trial Profile

Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 May 2015

At a glance

  • Drugs Denosumab (Primary) ; Teriparatide
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2015 Planned primary completion date changed from 1 Sep 2014 to 1 May 2015, as reported by ClinicalTrials.gov.
    • 21 Oct 2014 According to ClinicalTrials.gov, the protocol has been modified to include subjects ≥ 1 year and exclusion criteria are also modified.
    • 05 Sep 2014 Planned primary completion date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top